Evaluation of quality of life in adult patients with MS switching from injectable therapy i.e. Interferon (Avonex, Betaseron, Extavia, Rebif) or Copaxone® (glatiramer acetate) to oral medication Tecfidera® (BG00012) and their caregivers and evaluating their physical disability, cognitive function and adherence

ID Number 13-1822

Principal Investigator(s)
Aliza B Ben-Zacharia

Department(s) or Division(s)


The purpose of this study is to gather information on how the quality of life for people with relapsing Multiple Sclerosis (MS) who are taking an injectable form of medication for their MS is affected by switching to the oral medication Tecfidera.

Contact Information
Shelly Phelps
(212) 241-3391

Recruiting Patients: Yes